SPOTLIGHT: Novalar approval a small gain for big group


Novalar Pharmaceuticals may not have made drug history when the FDA approved their new therapy to speed the return of sensation after dental procedures, but the private biotech has some ambitious plans for marketing the drug. OraVerse goes on sale this fall at $12.50 a shot, promising to cut the amount of time spent drooling by about 75 to 85 minutes. Some people might call it trivial, but the experts say it addresses a real need. OraVerse release | Report

Suggested Articles

The NIH is starting with Eli Lilly and AbCellera's COVID-19 antibody but could add more prospects as the trial goes on.

The series B positions ex-AveXis executives to build a biotech with a broad gene therapy pipeline and infrastructure to match.

A variant of the ACE2 receptor could work as a COVID-19 therapeutic by drawing the virus away from healthy cells, scientists reported.